<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272557</url>
  </required_header>
  <id_info>
    <org_study_id>SoraDox</org_study_id>
    <nct_id>NCT01272557</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial</brief_title>
  <acronym>SoraDox</acronym>
  <official_title>Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Matthias Dollinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, open-label, multicenter phase IIB trial in order to
      determine time to progression of the combination therapy sorafenib plus doxorubicin against
      standard-of-care sorafenib in advanced HCC not amenable to non-systemic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP) according to RECIST 1.1 criteria</measure>
    <time_frame>The follow-up period ends 12 months after enrolment of the last patient (end of study visit of the last patient unless he died earlier</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response</measure>
    <time_frame>The follow-up period ends 12 months after enrolment of the last patient (end of study visit of the last patient unless he died earlier).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg bid (oral) continuously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).</description>
    <arm_group_label>q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 400 mg bid (oral) continuously</description>
    <arm_group_label>Sorafenib 400 mg bid (oral) continuously</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-resectable locally advanced or metastasized HCC

          -  Subjects must have at least one tumor lesion that meets both of the following
             criteria:

          -  the lesion can be accurately measured in at least one dimension according to RECIST
             1.1

          -  the lesion has not been previously treated with local therapy (such as surgery,
             radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency
             ablation, percutaneous ethanol injection or cryoablation)

          -  Subjects who have received local therapy (such as surgery, radiation therapy, hepatic
             arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol
             injection or cryoablation) are eligible, provided that they have a target lesion which
             has not been subjected to local therapy. Local therapy must be completed at least 4
             weeks prior to the baseline scan.

          -  Confirmation of disease by histology

          -  Liver function: Child Pugh stage A/B (5-7 points) only

          -  Tumor stage: BCLC stage C (or better)

          -  ECOG performance status 0-2

          -  Life expectancy of at least 12 weeks

          -  Age ≥ 18 years

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening and within 4 weeks
             before start of treatment:

          -  Hemoglobin ≥ 9.0 g/dl

          -  Absolute neutrophil count (ANC) ≥1.500/mm3

          -  Platelet count ≥ 70.000/μl

          -  Total bilirubin ≤ 3 mg/dl

          -  ALT and AST ≤ 5 x upper limit of normal

          -  Alkaline phosphatase &lt; 4 x upper limit of normal

          -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically
             anticoagulated with an agent such as warfarin, phenprocoumon or heparin will NOT be
             allowed to participate]

          -  Serum creatinine ≤ 1.5 x upper limit of normal

          -  Signed and dated informed consent before start of any study specific procedure

        Exclusion Criteria:

          -  Patients eligible for resection or transplantation

          -  Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study. However cervical carcinoma in situ, treated
             basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer
             curatively treated &gt; 3 years prior to entry is permitted

          -  Serious myocardial dysfunction: defined as absolute left ventricular ejection fraction
             (LVEF) &lt; 50%, instable coronaropathy (MI more than 6 mo prior to study entry is
             allowed), cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or
             digoxin are permitted)

          -  Inadequately controlled hepatic complications (varices, encephalopathy)

          -  Untreated active Hepatitis B including HBs-Ag carriers; patients should be started on
             (prophylactic) anti-viral medication even without current viral replication

          -  Concomitant therapy with interferon (e.g. Hepatitis B/C) during study phase

          -  Uncontrolled arterial hypertension with systolic blood pressure &gt;160 mmHg or diastolic
             blood pressure &gt; 90 mm Hg despite optimal treatment

          -  Known history of HIV infection

          -  Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)

          -  Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months
             from definitive therapy, has a negative imaging study within 4 weeks of study entry
             and is clinically stable with respect to the tumor at the time of study entry)

          -  Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics)

          -  History of organ allograft

          -  Patients with evidence or history of bleeding diathesis

          -  Thrombotic or embolic events within the last 6 months

          -  Serious non-healing wound, fracture, or ulcer

          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed within 7 days of the start of treatment. Women
             enrolled in this trial must use adequate barrier birth control measures during the
             course of the trial for at least 6 months after last administration of doxorubicin and
             2 months after the last administration of sorafenib.

          -  Severe concomitant disease or psychiatric disorders

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Known severe hypersensitivity to sorafenib, doxorubicin or any of the excipients

          -  Patients unable to swallow oral medications

          -  Incompliance / contraindications against study medication

        Excluded therapies and medications, previous and concomitant:

          -  Previous systemic therapy for HCC

          -  Anticancer chemotherapy or immunotherapy or targeted therapy (except study medication)
             during the study or within 4 weeks of study entry.

          -  Radiotherapy during study or within 3 weeks of start of study drug. (Palliative
             radiotherapy will be allowed). Major surgery within 4 weeks of start of study

          -  Autologous bone marrow transplant or stem cell rescue within 4 months of study

          -  Use of biologic response modifiers, such as G-CSF, within 3 week of study entry.
             [G-CSF and other hematopoietic growth factors may be used in the management of acute
             toxicity such as febrile neutropenia when clinically indicated or at the discretion of
             the investigator, however they may not be substituted for a required dose reduction.]
             [Patients taking chronic erythropoietin are permitted provided no dose adjustment is
             undertaken within 2 months prior to the study or during the study]

          -  Patients receiving anticoagulation therapy or ASS &gt;100 mg/d

          -  Investigational drug therapy outside of this trial during or within 4 weeks of study
             entry

          -  Prior exposure to the study drug.

          -  Any St. John's wort containing remedy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>D-06099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlande</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Lahr-Ettenheim</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04013</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Matthias Dollinger</investigator_full_name>
    <investigator_title>PD. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

